Factors associaeed to adherence to different tratment schemes with meglumine aantimoniate in a clinical trial for cutaneous leishmaniasis

Ribeiro, Madelon Novato; Pimentel, Maria Inês Fernandes; Schubach, Armando de Oliveira; Oliveira, Raquel de Vasconcellos Carvalhães de; Teixeira, José Liporage; Leite, Madson Pedro da Silva; Fonseca, Monique; Santos, Ginelza Peres Lima dos; Salgueiro, Mariza Matos; Vasconcellos, Erica de Camargo Ferreira e; Lyra, Marcelo Rosandiski; Saheki, Mauricio Naoto; Valete-Rosalino, Claudia Maria.
Rev. Inst. Med. Trop. Säo Paulo ; 56(4): 291-296, Jul-Aug/2014. tab
Artigo em Inglês | LILACS | ID: lil-716424

Similares

  1. Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.
  2. Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013).
  3. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
  4. Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment.
  5. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre.
  6. Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial.
  7. Owners' experiences of administering meglumine antimoniate injections to dogs with leishmaniosis: An online questionnaire study.
  8. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis.
  9. Evaluation of various biomarkers for kidney monitoring during canine leishmaniosis treatment.
  10. Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis.